Zobrazeno 1 - 10
of 690
pro vyhledávání: '"E. K. Rowinsky"'
Autor:
Chen, Yu1 (AUTHOR), Dai, Liqun1 (AUTHOR), Shi, Kun1 (AUTHOR), Pan, Meng1 (AUTHOR), Yuan, Liping1 (AUTHOR), Qian, Zhiyong1 (AUTHOR) zhiyongqian@scu.edu.cn
Publikováno v:
Advanced Science. 9/4/2024, Vol. 11 Issue 33, p1-11. 11p.
Autor:
E. K. Rowinsky
Publikováno v:
The Oncologist. 8:5-17
Autor:
E. K. Rowinsky
Publikováno v:
The Oncologist. 8:1-4
Autor:
Zhou X; College of Pharmaceutical Sciences, State Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, 866 Yuhangtang Road, Hangzhou, 310058, China., Zhang P; Center of Drug Discovery, State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, 24 Tongjiaxiang Road, Nanjing, 210009, China., Yang Y; College of Pharmaceutical Sciences, State Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, 866 Yuhangtang Road, Hangzhou, 310058, China., Shi W; Center of Drug Discovery, State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, 24 Tongjiaxiang Road, Nanjing, 210009, China., Liu L; College of Pharmaceutical Sciences, State Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, 866 Yuhangtang Road, Hangzhou, 310058, China., Lai Z; College of Pharmaceutical Sciences, State Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, 866 Yuhangtang Road, Hangzhou, 310058, China., Zhang X; College of Pharmaceutical Sciences, State Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, 866 Yuhangtang Road, Hangzhou, 310058, China., Pan P; College of Pharmaceutical Sciences, State Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, 866 Yuhangtang Road, Hangzhou, 310058, China., Li L; Department of Gastroenterology, T, he First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China., Du J; Department of Gastroenterology, T, he First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China., Qian H; Center of Drug Discovery, State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, 24 Tongjiaxiang Road, Nanjing, 210009, China., Cui S; College of Pharmaceutical Sciences, State Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, 866 Yuhangtang Road, Hangzhou, 310058, China.
Publikováno v:
Angewandte Chemie (International ed. in English) [Angew Chem Int Ed Engl] 2024 Nov 04; Vol. 63 (45), pp. e202412649. Date of Electronic Publication: 2024 Sep 17.
Autor:
E. Campbell, J. G. Kuhn, Anthony W. Tolcher, J. Rizzo, Geoffrey R. Weiss, Elzbieta Izbicka, E. K. Rowinsky, C. Aylesworth, D. D. Von Hoff
Publikováno v:
Annals of Oncology. 11:333-338
Summary Background; Rhizoxin (NSC 332598) is a novel macrolide antitumor antibiotic that inhibits microtubule assembly and also depolymerizes preformed microtubules. In preclinical evaluations, rhizoxin demonstrated broad antitumor activity in vitro
Autor:
D. D. Von Hoff, Eric Raymond, E. K. Rowinsky, Axel-R. Hanauske, Gary M. Clark, Sandrine Faivre, Elzbieta Izbicka
Publikováno v:
Anti-Cancer Drugs. 8:379-385
Paclitaxel shows a broad clinical activity in ovarian, breast and non-small cell lung cancers. However, controversy remains about the respective effects of doses and schedules in paclitaxel cytotoxicity. This study was conducted to compare the cytoto
Autor:
Michael T. Crow, Edward G. Lakatta, E K Rowinsky, Rebecca R. Pauly, Jeffrey P. Froehlich, Robert E. Monticone, Masafumi Kuzuya, Linda Cheng, Steven J. Sollott, G M Jenkins
Publikováno v:
Journal of Clinical Investigation. 95:1869-1876
Despite significant improvements in the primary success rate of the medical and surgical treatments for atherosclerotic disease, including angioplasty, bypass grafting, and endarterectomy, secondary failure due to late restenosis continues to occur i
Autor:
Huang, Jiaqi1,2 (AUTHOR), Yin, Qianqian2,3,4 (AUTHOR), Wang, Yuqing2,4 (AUTHOR), Zhou, Xin4,5 (AUTHOR), Guo, Yunyun1,2 (AUTHOR), Tang, Yuanjun2,4 (AUTHOR), Cheng, Rui1,2 (AUTHOR), Yu, Xiaotong2,4 (AUTHOR), Zhang, Jie2,4 (AUTHOR), Huang, Chen2,4 (AUTHOR), Huang, Zhanya1,2 (AUTHOR), Zhang, Jianlin2,4 (AUTHOR), Guo, Zhengyang2,4 (AUTHOR), Huo, Xiao2,3,4 (AUTHOR), Sun, Yan2,4 (AUTHOR), Li, Yanfang2,4 (AUTHOR), Wang, Hao1,4 (AUTHOR) wanghaobysy@bjmu.edu.cn, Yang, Jianling2,4 (AUTHOR) jianlingyang@bjmu.edu.cn, Xue, Lixiang1,2,3,4,6 (AUTHOR) lixiangxue@hsc.pku.edu.cn
Publikováno v:
Advanced Science. 6/19/2024, Vol. 11 Issue 23, p1-18. 18p.
Autor:
Jennifer L. Spratlin, Roger B. Cohen, S. Gail Eckhardt, Laura Q.M. Chow, Matthew Eadens, Cindy L. O'Bryant, E. K. Rowinsky, Nancy L. Lewis, E. Gabriela Chiorean, Natalie J. Serkova, Lia Gore, Sami Diab, D. Ross Camidge, Stephen Leong, N. J. Meropol, Floyd Fox, Hagop Youssoufian
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(5)
Purpose To evaluate the safety, maximum-tolerated dose (MTD), pharmacokinetics (PKs), pharmacodynamics, and preliminary anticancer activity of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothe
Publikováno v:
Blood. 75:1319-1323
Bryostatin 1, a macrocyclic lactone isolated from the marine bryozoan Bugula neritina, has demonstrated both antineoplastic activity against the murine P388 leukemia line in vivo and stimulatory activity against mouse and human hematopoietic progenit